Another concern regarding GLP-1 RA use that has arisen in recent years due to a clinical trial with liraglutide was an increased risk of melanoma; however, further investigation in a population-based cohort study has shown no association of increased risk of melanoma or non-melanoma skin cancer with GLP-1 RAs use compared to sulfonylureas in patients with T2DM [12]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.